SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Genetic Technologies Limited GENE NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • AU • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Genetic Technologies Limited (GENE) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.77. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $8M, +1854.2%/yr average growth. Net income is $12M (loss), growing at -22.6%/yr. Net profit margin is -156.8% (negative). Gross margin is 50.9% (+250.4 pp trend).

Balance sheet: total debt is $875,189 against $2M equity (Debt-to-Equity (D/E) ratio 0.48, conservative). Current ratio is 0.88 (tight liquidity). Debt-to-assets is 14.1%. Total assets: $6M.

Analyst outlook: 0 / 1 analysts rate GENE as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

GENE SharesGrow Score Overview

34/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GENE

No analyst coverage available for this stock.

GENE: +1854.2%/yr revenue is, -22.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet GENE: Debt-to-Equity (D/E) ratio 0.48 (conservative), Current ratio is 0.88 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

GENE: Gross margin is 50.9% (+250.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 1 analysts rate GENE as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

GENE: Net profit margin is -156.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.6666-3.59

Market Cap$111.24M

Beta (1Y)0.48

Share Statistics

EPS (TTM)-2.73

Shares Outstanding$4.41M

IPO Date2005-09-06

Employees55

CEOKevin Camilleri

Financial Highlights & Ratios

Revenue (TTM)$7.66M

Gross Profit$3.9M

EBITDA$-11.43M

Net Income$-12.02M

Operating Income$-6.54M

Total Cash$1.04M

Total Debt$875.19K

Net Debt$-145.42K

Total Assets$6.19M

Price / Earnings (P/E)-0.3

Price / Sales (P/S)14.51

Analyst Forecast

Rating ConsensusSell

Analysts Covering1

Buy 0% Hold 0% Sell 100%

Company Info

CountryAU

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS37185R4065

Price Chart

GENE

Genetic Technologies Limited ↗ · NASDAQ Capital Marke

Healthcare • Medical - Diagnostics & Research

0.67 52WK RANGE 3.59

People Also View

Agilent Technologies, Inc.

Sera Prognostics, Inc.

bioAffinity Technologies, Inc.

Interpace Biosciences, Inc.

Intelligent Bio Solutions Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message